Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American ophthalmological society thesis)

Transactions of the American Ophthalmological Society

Volumn 104, Issue , 2006, Pages 322-345

  Blomquist, Preston Howard ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DICLOXACILLIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; TETRACYCLINE; TOBRAMYCIN; VANCOMYCIN;

ABSCESS; ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; BACTERIAL EYE INFECTION; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CELLULITIS; CHILD; COMORBIDITY; CONJUNCTIVITIS; CORNEA ULCER; ENDOPHTHALMITIS; EYELID; FEMALE; HOSPITAL INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; ORBIT CELLULITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; STAPHYLOCOCCUS INFECTION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; EYE INFECTIONS, BACTERIAL; FEMALE; HOSPITALS, COUNTY; HUMANS; INFANT; MALE; METHICILLIN; METHICILLIN RESISTANCE; MIDDLE AGED; ORBITAL DISEASES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEXAS; URBAN POPULATION;

EID: 33947686663     PISSN: None     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Review

References (221)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339:520-532.
2. Novick RP. The staphylococcus as a molecular genetic system. In: Novick RP, ed. Molecular Biology of the Staphylococci. New York: VCH; 1990:1-37.
3. Schaberg DR, Zervos MJ. Intergeneric and interspecies gene exchange in gram-positive cocci. Antimicrob Agents Chemother 1986;30:817-822.
4. Noble WC, Valkenburg HA, Wolters CHL. Carriage of Staphylococcus aureus in random samples of a normal population. J Hyg (Lond) 1967;65:567-573.
5. Casewell MW, Hill RLR. The carrier state: methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1986;18(Suppl A):1-12.
6. Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect 1995;31:13-24.
7. Brumfitt W, Hamilton-Miller J. Methicillin-resistant Staphylococcus aureus. N Engl J Med 1989;320:1188-1196.
8. Kirby WM. Extraction of a high potent penicillin inactivator from penicillin resistant staphylococci. Science 1944;99:452-453.
9. Barber M, Rozwadowska-Dowzenko M. Infection by penicillin-resistant staphylococci. Lancet 1948;1:641-644.
10. Kaye KS, Engemann JJ, Fraimow HS, et al. Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am 2004;18:467-511.
11. Barber M, Rozwadowska-Dowzenko M. Infection by penicillin-resistant staphylococci. Lancet 1948;2:641-644.
12. Jessen O, Rosendal K, Bulow P, et al. Changing staphylococci and staphylococcal infections. A ten-year study of bacteria and cases of bacteremia. N Engl J Med 1969;281:627-635.
13. Ross S, Rodriguez W, Controni G, et al. Staphylococcal susceptibility to penicillin G. The changing pattern among community strains. JAMA 1974;229:1075-1077.
14. Hughes GB, Chidi CC, Macon WL. Staphylococci in community-acquired infections: increased resistance to penicillin. Ann Surg 1976;183:355-357.
15. Hahn DL, Baker WA. Penicillin G susceptibility of "rural" Staphylococcus aureus. J Fam Pract 1980;11:43-46.
16. Robinson GN, Stevens S, Batchelor FR, et al. Bacteriological studies on a new penicillin - BRL.1241. Lancet 1960;2:564-567.
17. Jevons MP. "Celbenin"-resistant staphylococci. Br J Med 1961;1:124-125.
18. Knox R. "Celbenin"-resistant staphylococci. Br J Med 1961;1:126.
19. Gedney J, Lacey RW. Properties of methicillin-resistant staphylococci now endemic in Australia. Med J Aust 1982;1:448-450.
20. Pavillard R, Harvey K, Douglas D, et al. Epidemic of hospital-acquired infection due to methicillin-resistant Staphylococcus aureus in major Victorian hospitals. Med J Aust 1982;1:451-454.
21. Sahm DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database - USA. Clin Infect Dis 1999;29:259-263.
22. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphyoccocal species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997 - 1999. Clin Infect Dis 2001;32(suppl 2):S114-S132.
23. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593-598.
24. Centers for Disease Control and Prevention. Four pediatric deaths from community acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997 - 1999. MMWR Morb Mortal Wkly Rep 1999;48:707-710.
25. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison - Mississippi 2000. MMWR Morb Mortal Wkly Rep 2001;50:919-922.
26. Centers for Disease Control and Prevention. Outbreaks of community-acquired methicillin-resistant Staphylococcus aureus skin infections - Los Angeles County, California, 2002 - 2003. MMWR Morb Mortal Wkly Rep 2003;52:88.
27. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus infections among competitive sports participants - Colorado, Indiana, Pennsylvania and Los Angeles County, 2000 - 2003. MMWR Morb Mortal Wkly Rep 2003;52:793-795.
28. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus infections in correctional facilities - Georgia, California and Texas, 2001 - 2003. MMWR Morb Mortal Wkly Rep 2003;52:992-996.
29. Zetola N, Francis JS, Nuermberger EL, et al. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005;5:275-286.
30. Shanmuganathan VA, Armstrong M, Buller A, et al. External ocular infections due to methicillin-resistant Staphylococcus aureus (MRSA). Eye 2005;19:284-291.
31. Muder RR, Brennen C, Wagener MM, et al. Methicillin-resistant staphylococcal colonization and infection in a long-term care facility. Ann Intern Med 1991;114:107-112.
32. Leman R, Alvarado-Ramy F, Pocock S, et al. Nasal carriage of methicillin-resistant Staphylococcus aureus in an American Indian population. Infect Hosp Control Epidemiol 2004;25:121-125.
33. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-59.
34. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: At what costs? Infect Control Hosp Epidemiol 1999;20:408-411.
35. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-598.
36. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in non-addicts. Ann Intern Med 1982;97:496-503.
37. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988;109:619-624.
38. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990;34:1227-1231.
39. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674-680.
40. Hartstein AI, Mulligan ME, Morthland VH, et al. Recurrent Staphylococcus aureus bacteremia. J Clin Microbiol 1992;30:670-674.
41. Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA 1995;274:1706-1713.
42. Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29:1171-1177.
43. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987;316:927-931.
44. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-136.
45. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiologic and microbiologic characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997 - 2001. Clin Infect Dis 2003;36:429-439.
46. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-567.
47. Chang S, Sievert DM, Hagerman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-1347.
48. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72:195-198.
49. Ribner BS. Endemic, multiply resistant Staphylococcus aureus in a pediatric population. Am J Dis Child 1987;141:1183-1187.
50. Ross J, Abate MA. Topical vancomycin for the treatment of Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus conjunctivitis. DICP 1990;24:1050, 1053.
51. Fukuda M, Ohashi H, Matsumoto C, et al. Methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative Staphulococcus ocular surface infection: efficacy of chloramphenicol eye drops. Cornea 2002;21(7 suppl):S86-S89.
52. Brennen C, Muder RR. Conjunctivitis associated with methicillin-resistant Staphylococcus aureus in a long-term-care facility. Am J Med 1990;88(5N):14N-17N.
53. Rubin LG, Tucci V, Cercenado E, et al. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect Control Hosp Epidemiol 1992;13:700-705.
54. Spindel SJ, Strausbaugh LJ, Jacobson C. Infections caused by Staphylococcus aureus in a veterans' affairs nursing home care unit: a 5-year experience. Infect Control Hosp Epidemiol 1995;16:217-223.
55. Horil T, Futamura N, Suzuki Y. Antiseptic treatment of methicillin-resistant Staphylococcus aureus conjunctivitis. J Infect 2001;42:166-169.
56. Mitsuda T, Arai K, Fujita S, et al. Epidemiological analysis of strains of methicillin-resistant Staphylococcus aureus (MRSA) infection in the nursery; prognosis of MRSA carrier infants. J Hosp Infect 1995;31:123-134.
57. Hayakawa T, Hayashidera T, Yoneda K, et al. Unexpectedly prolonged colonization of exfoliative toxin A-producing methicillin-resistant Staphylococcus aureus in infants. Eur J Pediatr 1998;157:781.
58. Jernigan JA, Titus MG, Groschel DH, et al. Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus. Am J Epidemiol 1996;143:496-504.
59. Saiman, L, Cronquist A, Wu F, et al. An outbreak of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2003;24:317-321.
60. Muder RR, Brennen C, Goetz AM. Infection with methicillin-resistant Staphylococcus aureus among hospital employees. Infect Control Hosp Epidemiol 1993;14:576-578.
61. Maskin SL. Infectious scleritis after a diabetic foot ulcer. Am J Ophthalmol 1993;115:254-255.
62. Eiferman RA, O'Neill KP, Morrison NA. Methicillin-resistant Staphylococcus aureus corneal ulcers. Ann Ophthalmol 1991;23:414-415.
63. Insler MS, Fish LA, Silbernagel J, et al. Successful treatment of methicillin-resistant Staphylococcus aureus keratitis with topical ciprofloxacin. Ophthalmology 1991;98:1690-1692.
64. Sotozono C, Inagaki K, Fujita A, et al. Methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylcoccus aureus infections in the cornea. Cornea 2002;21(7 suppl):S94-S101.
65. Inoue Y. Ocular infections in patients with atopic dermatitis. Int Ophthalmol Clin 2002;42:55-69.
66. Labit CM, Claeys GW, Verbraeken HE, et al. Methicillin resistance of bacteria isolated from vitreous fluid from patients undergoing vitrectomy. Eur J Ophthalmol 2001;11:160-165.
67. Saitoh A, Jinbayashi H, Saitoh AK, et al. Parameter estimation and dosage adjustment in the treatment with vancomycin of methicillin-resistant Staphylococcus aureus ocular infections. Ophthalmologica 1997;211:232-235.
68. Kubo M, Sakuraba T, Arai Y, et al. Dacryocystorhinostomy for dacryocystitis caused by methicillin-resistant Staphylococcus aureus: report of four cases. Jpn J Ophthalmol 2002;46:177-182.
69. Mehra P, Caiazzo A, Bestgen S. Odontogenic sinusitis causing orbital cellulitis. JADA 1999;130:1086-1092.
70. Anari S, Karagama YG, Fulton B, et al. Neonatal disseminated methicillin-resistant Staphylococcus aureus presenting as orbital cellulitis. J Laryngol Otol 2005;119:64-67.
71. Kato T, Hayasaka S. Methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative Staphylococci from conjunctivas of preoperative patients. Jpn J Ophthalmol 1988;42:461-465.
72. Cosar CB, Cohen EJ, Rapuano CJ, et al. Clear corneal wound infection after phacoemulsification. Arch Ophthalmol 2001;119:1755-1759.
73. Chiang RK, Rapuano CJ. Recurrent methicillin-resistant Staphylococcus aureus wound ulcer after clear-cornea cataract surgery. CLAO J 2002;28:109-110.
74. Moshirfar M, Marx DP, Mirzaian G. Endophthalmitis in patients using fourth-generation fluoroquinolones following phacoemulsification. J Cataract Refract Surg 2005;31:1669-1670.
75. Rudd JC, Moshirfar M. Methicillin-resistant Staphylococcus aureus keratitis after laser in situ keratomileusis. J Cataract Refract Surg 2001;27:471-473.
76. Rubenfeld RS, Negvesky GJ. Methicillin-resistant Staphylococcus aureus ulcerative keratitis after laser in situ keratomileusis. J Cataract Refract Surg 2001;27:1523-1525.
77. Förster W, Becker K, Hungermann D, et al. Methicillin-resistant Staphylococcus aureus after excimer laser photorefractive keratectomy. J Cataract Refract Surg 2002;28:722-724.
78. Solomon R, Donnenfeld ED, Perry HD, et al. Bilateral methicillin- resistant Staphylococcus aureus keratitis in a medical resident following an uneventful bilateral photorefractive keratectomy. Eye Contact Lens 2003;29:187-189.
79. Donnenfeld ED, O'Brien TP, Solomon R, et al. Infectious keratitis after photorefractive keratectomy. Ophthalmology 2003;110:743-747.
80. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1974;90:525-530.
81. Hanifin JM, Rogge JL. Staphylococcal infections in patients with atopic dermatitis. Arch Dermatol 1993;103:1315-1322.
82. Hoeger PH, Lenz W, Boutonnier A, et al. Staphylococcal skin colonization in children with atopic dermatitis: prevalence, persistence, and transmission of toxigenic and nontoxigenic strains. J Infect Dis 1992;165:1064-1068.
83. Oshima Y, Ohji M, Inoue Y, et al. Methicillin-resistant Staphylococcus aureus infections after scleral buckling procedures for retinal detachments associated with atopoic dermatitis. Ophthalmology 1999;106:142-147.
84. Osawa S, Sasoh M, Ito K, et al. Exudative retinal detachment due to methicillin-resistant Staphylococcal aureus after scleral buckling in the treatment of retinal detachment accompanied by atopic dermatitis. Retina 2002;22:649-651.
85. Clinical and Laboratory Standards Institute/NCCLS. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement. CLSI/NCCLS Document M100-S15. Wayne, Pennsylvania: CLSI; 2005.
86. Palavecino E. Community-acquired methicillin-resistant Staphyloccus aureus infections. Clin Lab Med 2004;24:403-418.
87. Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis and chemical implications. Clin Microbiol Rev 1997;10:781-791.
88. Katayama Y, Zhang HZ, Hong D, et al. Jumping the barrier to beta-lactam resistance in Staphylococcus aureus. J Bacteriol 2003;185:5465-5472.
89. Asheshov EH, Dyke KG. Regulation of the synthesis of penicillinase in diploids of Staphylococcus aureus. Biochem Biophys Res Commun 1968;30:213-218.
90. Sabath LD. Mechanisms of resistance of beta-lactam antibiotics in strains of Staphylococcus aureus. Ann Intern Med 1982;97:339-344.
91. Ito T, Katayama Y, Asada K, et al. Structural comparison of three types of staphylococcal cassette chromosome mec in the chromosome of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001;45:1323-1326.
92. Hiramatsu K. Molecular evolution of MRSA. Microbiol Immunol 1995;39:531-543.
93. Hiramatsu K, Cui L, Kuroda M, et al. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 2001;9:486-493.
94. Archer GL, Niemeyer DM. Origin and evolution of DNA associated with resistance to methicillin in staphylococci. Trends Microbiol 1994;2:343-347.
95. Enright MC, Robinson DA, Randle G, et al. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci USA 2002:99:7687-7692.
96. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of mulitdrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003;24:362-386.
97. Ito T, Okuma K, Ma XX, et al. Insights on antibiotic resistance of Staphylococcus aureus from its whole genome: genomic island SCC. Drug Resist Updates 2003;6:41-52.
98. Ito T, Ma XX, Takeuchi F, et al. Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Agents Chemother 2004;48:2637-2651.
99. Enright MC, Day NP, Davies CE, et al. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 2000;38:1008-1015.
100. Ma XX, Ito T, Tiensasitorn C, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002;46:1147-1152.
101. Fey PD, Said-Salim B, Rupp ME, et al. Comparative molecular analysis of community or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:196-203.
102. Oliveira DC, Tomasz A, de Lencastre H. Secrets of success of a human pathogen: molecular evolution of pandemic clones of methicillin-resistant Staphylococcus aureus. Lancet Infect Dis 2002;2:180-189.
103. Charlebois ED, Perdreau-Remington F, Kreiswirth B, et al. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004;39:47-54.
104. Kreiswirth B, Kornblum J, Arbeit RD, et al. Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus. Science 1993;259:227-230.
105. Oliveira DC, Tomasz A, de Lancastre H. The evolution of pandemic clones of methicillin-resistant Staphylococcus aureus: identification of two ancestral genetic backgrounds and the associated mec elements. Microb Drug Resist 2001;7:349-361.
106. Musser J, Kapur V. Clonal analysis of methicillin-resistant Staphylococcus aureus from intercontinental sources: association of the mec gene with divergent phylogenetic lineages implies dissemination by horizontal transfer and recombination. J Clin Microbiol 1992;30:2058-2063.
107. Givney R, Vickery A, Holliday A, et al. Evolution of an endemic methicillin-resistant Staphylococcus aureus population in an Australian hospital from 1967 - 1996. J Clin Microbiol 1998;36:552-556.
108. Crisostomo MI, Westh H, Tomasz A, et al. The evolution of methicillin resistance in Staphylococcus: similarity of genetic backgrounds in historically early methicillin-susceptible and resistant and contemporary epidemic clones. Proc Natl Acad Sci USA 2001;98:9865-9870.
109. Farr BM. Prevention and control of methicillin-resistant Staphylococcus aureus infections. Curr Opin Infect Dis 2004;17:317-322.
110. Holmes O. The contagiousness of puerperal fever. N Engl Q J Med Surg 1842 - 1843;1:501-530.
111. Semmelweis I. The Etiology, the Concept and the Prophylaxis of Childbed Fever. Pest, Hungary: CA Hartleben's Verlag-Expedition, 1861.
112. Cooper BS, Stone SP, Kibbler CC, et al. Isolation measures in the hospital management of methicillin resistant Staphylococcus aureus (MRSA): systematic review of the literature. BMJ 2004;329:533-538.
113. Boyce JM, Potter-Bynoe G, Chenevert C, et al. Environmental contamination due to methicillin-resistant Staphylococcus aureus: possible infection control implications. Infect Control Hosp Epidemiol 1997;18:622-627.
114. Bhalla A, Pultz, NJ, Gries DM, et al. Acquisition of nosocomial pathogens on hands after contact with environmental surfaces near hospitalized patients. Infect Control Hosp Epidemiol 2004;25:164-167.
115. Devine J, Cooke RP, Wright EP. Is methicillin-resistant Staphylococcus aureus (MRSA) contamination of ward-based computer terminals a surrogate marker for nosocomial MRSA transmission and handwashing compliance? J Hosp Infect 2001;48:72-75.
116. Layton MC, Perez M, Heald P, et al. An outbreak of mupirocin-resistant Staphylococcus aureus on a dermatology ward associated with an environmental reservoir. Infect Control Hosp Epidemiol 1993;14:369-375.
117. Neely AN, Maley MP. Survival of enterococci and staphylococci on hospital fabrics and plastics. J Clin Microbiol 2000;38:724-726.
118. Dietz B, Raht A, Wendt C, et al. Survival of MRSA on sterile goods packaging. J Hosp Infect 2001;49:255-261.
119. Borg MA. Bed occupancy and overcrowding as determinant factors in the incidence of MRSA infections within general ward settings. J Hosp Infect 2003;54:316-318.
120. Haley RW, Cushion NB, Tenover FC, et al. Eradication of endemic methicillin-resistant Staphylococcus aureus infections from a neonatal intensive care unit. J Infect Dis 1995;171:614-624.
121. Herr CE, Heckrodt TH, Hofmann FA, et al. Additional costs for preventing the spread of methicillin-resistant Staphylococcus aureus and a strategy for reducing these costs on a surgical ward. Infect Control Hosp Epidemiol 2003;24:673-678.
122. Thompson RL, Cabezudo I, Wenzel RP. Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982;97:309-317.
123. Back NA, Linnemann CC Jr, Staneck JL, et al. Control of methicillin-resistant Staphylococcus aureus in a neonatal intensive-care unit: use of intensive microbiologic surveillance and mupirocin. Infect Control Hosp Epidemiol 1996;17:227-231.
124. Salmenlinna S, Lyytikainen O, Kotilaninen P, et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus in Finland. Eur J Clin Microbiol Infect Dis 2000;19:101-107.
125. Verhoef J, Beaujean D, Blok H, et al. A Dutch approach to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1999;18:461-466.
126. Kotilainen P, Routamaa M, Peltonen R, et al. Elimination of epidemic methicillin-resistant Staphylococcus aureus from a university hospital and district institutions, Finland. Emerg Infect Dis 2003;9:169-175.
127. Lucet JC, Chevret S, Durand-Zaleske I, et al. Prevalence and risk factors for carriage of methicillin-resistant Staphylococcus aureus at admission to the intensive care unit: results of a multicenter study. Arch Intern Med 2003;163:181-188.
128. Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. JAMA 2003;290:1899-1905.
129. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7:178-182.
130. Chambers HF. Community-associated MRSA - resistance and virulence converge. N Engl J Med 2005;352:1485-1487.
131. Frank AL, Marcinak JF, Mangat PD, et al. Increase in community-acquired methicillin-resistant Staphylococcus aureus in children. Clin Infect Dis 1999;29:935-936.
132. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005;352:1445-1453.
133. Young DM, Harris HW, Charlebois ED, et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissues infections among medically underserved patients. Arch Surg 2004;139:947-953.
134. Frazee BW, Lynn J, Charlebois ED, et al. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 2005;45:311-320.
135. Daum RS, Ito T, Hiramatsu K, et al. A novel methicillin-resistant cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis 2002;186:1344-1347.
136. Wielders CL, Vriens MR, Brisse S, et al. In-vivo transfer of mecA DNA to Staphylococcus aureus. Lancet 2001;357:1674-1675.
137. Baba T, Takeuchi F, Kuroda M, et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002;359:1819-1827.
138. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community-acquired and health care-associated methicillin-resistant Staphyloccus aureus infection. JAMA 2003;290:2976-2984.
139. McDougal LK, Steward CD, Killgore GE, et al. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003;41:5113-5120.
140. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin- resistant Staphylococcus aureus among professional football players. N Engl J Med 2005;352:468-475.
141. Robinson DA, Enright MC. Multilocus sequence typing and the evolution of methicillin-resistant Staphylococcus aureus. Clin Microb Infect 2004;10:92-97.
142. Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin- resistant Staphylococcal aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002;35:819-824.
143. Ala'Aldeen D. A non-multiresistant community methicillin-resistant Staphylococcus aureus exposes its genome. Lancet 2002;359:1791-1792.
144. Vandenesch F, Naimi T, Enright MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003;9:978-984.
145. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29:1128-1132.
146. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-1444.
147. Dominguez TJ. It's not a spider bite, it's community-acquired methicillin-resistant Staphylococcus aureus. J Am Board Fam Pract 2004;17:220-226.
148. Baggett HC, Hennessy TW, Leman R, et al. An outbreak of community-onset methicillin-resistant Staphylococcus aureus skin infections in southwestern Alaska. Infect Control Hosp Epidemiol 2003;24:397-402.
149. Charlebois ED, Bangsberg DR, Moss NJ, et al. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis 2002;34:425-433.
150. Groom AV, Wolsey DH, Naimi TS, et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001:286;1201-1205.
151. Charlebois ED, Bangsberg DR, Moss NJ, et al. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis 2002;34:425-433.
152. Fleisch F, Zbinden R, Vanoli C, et al. Epidemic spread of a single clone of methicillin-resistant Staphylococcus aureus among injection drug users in Zurich, Switzerland. Clin Infect Dis 2001;32:581-586.
153. Pan ES, Diep BA, Carleton HA, et al. Increasing prevalence of methicillin-resistant Staphylococcus aureus infection in California jails. Clin Infect Dis 2003;37:1384-1388.
154. Horan TC, Gaynes RP. Surveillance of nosocomial infections. In: Mayhall CG, ed. Hospital Epidemiology and Infection Control, 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004:1659-1702.
155. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003;36:131-139.
156. Friedman ND, Kaye KS, Stout JE, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002;137:791-797.
157. Lesens O, Hansmann Y, Brannigan E, et al. Healthcare-associated Staphylococcus aureus bacteremia and the risk for methicillin resistance: Is the Centers for Disease Control and Prevention definition for community-acquired bacteremia still appropriate? Infect Control Hosp Epidemiol 2005;26:204-209.
158. Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin- resistant Staphylococcus aureus. Pediatr Infect Dis J 2004;23:123-127.
159. Mandelbaum S, Forster RK, Gelender H, et al. Late onset endophthalmitis associated with filtering blebs. Ophthalmology 1985;92:964-972.
160. Greenfield DS, Suner IJ, Miller MP, et al. Endophthalmitis after filtering surgery with mitomycin C. Arch Ophthalmol 1996;114:943-949.
161. Kangas TA, Greenfield DS, Flynn HW Jr, et al. Delayed-onset endophthalmitis associated with conjunctival filtering blebs. Ophthalmology 1997;104:746-752.
162. Waheed S, Ritterband DC, Greenfield DS, et al. Bleb-related ocular infection in children after trabeculectomy with mitomycin C. Ophthalmology 1997;104:2117-2120.
163. Akova YA, Bulut S, Dabil H, et al. Late bleb-related endophthalmitis after trabeculectomy with mitomycin C. Ophthalmic Surg Lasers 1999;30:146-151.
164. Lam RF, Hui M, Leung DY, et al. Extent and predictors of microbial hand contamination in a tertiary care ophthalmic outpatient practice. Invest Ophthalmol Vis Sci 2005;46:3578-3583.
165. Larson E, Leyden JJ, McGinley KJ, et al. Physiologic and microbiologic changes in skin related to frequent handwashing. Infect Control 1986;7:59-63.
166. Doebbeling BN, Stanley GL, Sheetz CT, et al. Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units. N Engl J Med 1992;327:88-93.
167. Fraise AP. Guidelines for the control of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1998;42:287-289.
168. Fleischer AB, Hoover DL, Khan JA, et al. Topical vancomycin formulation for methicillin-resistant Staphylococcus epidermidis blepharoconjunctivitis. Am J Ophthalmol 1986;101:283-287.
169. Khan JA, Hoover D, Ide CH. Methcillin-resistant Staphylococcus epidermidis blepharitis. Am J Ophthalmol 1984;98:562-565.
170. Goodman DF, Gottsch JD. Methicillin-resistant Staphylococcus epidermidis keratitis treated with vancomycin. Arch Ophthalmol 1988;106:1570-1571.
171. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44(RR-12):1-13.
172. Mariana MD, Colby KA. Evaluation and initial management of patients with ocular and adnexal trauma. In: Albert DM, Jakobiec FA, Azar DT, et al, eds. Principles and Practice of Ophthalmology, 2nd ed. Philadelphia: WB Saunders; 2000:5180-5200.
173. Gills JP. Filter and antibiotics in irrigating solution for cataract surgery. J Cataract Refract Surg 1991;17:385.
174. West ES, Behrens A, McDonnell PJ, et al. The incidence of endophthalmitis after cataract surgery among the US Medicare population increased between 1994 and 2001. Ophthalmology 2005;112:1388-1394.
175. Gordon YJ. Vancomycin prophylaxis and emerging resistance: Are ophthalmologists the villains? The heroes? Am J Ophthalmol 2001;131:371-376.
176. Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery. An evidence-based update. Ophthalmology 2002;109:13-26.
177. AAO-CDC Task Force on Vancomycin Prophylaxis in Ophthalmic Surgery. The prophylactic use of vancomycin for intraocular surgery. Quality of Care Publications, Number 515. San Francisco: American Academy of Ophthalmology; 1999.
178. Ferro J, De-Pablos M, Logrono M. Postoperative contamination after vancomycin and gentamicin during phacoemulsification. Arch Ophthalmol 1997;115:165-170.
179. Feys J, Salvanet-Bouccara A, Edmond JP, et al. Vancomycin prophylaxis and intraocular contamination during cataract surgery. J Cataract Refract Surg 1997;23:894-897.
180. Kodjikian L, Renaud FN, Roques C, et al. In vitro influence of vancomycin on adhesion of a Staphylococcus epidermidis strain encoding intercellular adhesion locus ica to intraocular lenses. J Cataract Refract Surg 2005;31:1050-1058.
181. McCulley JP. Low acute endophthalmitis rate: possible explanations. J Cataract Refract Surg 2005;31:1074-1075.
182. Fry LL. Vancomycin dilution error. J Cataract Refract Surg 2005;31:1674.
183. Axel-Siegel R, Stiebel-Kalish H, Rosenblatt I, et al. Cystoid macular edema after cataract surgery with intraocular vancomycin. Ophthalmology 1999;106:1660-1664.
184. Libre PE, Della-Latta P, Chin N. Intracameral antibiotic agents for endophthalmitis prophylaxis. A pharmacokinetic model. J Cataract Refract Surg 2003;29:1791-1794.
185. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol 2004;49(suppl 2):S79-S83.
186. Gaynor BD, Chidambaram JD, Cevallos V, et al. Topical ocular antibiotics induce bacterial resistance at extraocular sites. Br J Ophthalmol 2005;89:1097-1099.
187. Boyce JM, Pittet D. Guidelines for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol 2002;23(12 suppl):S3-S40.
188. Olsen RJ, Lynch P, Coyle MB, et al. Examination gloves as barriers to hand contamination in clinical practice. JAMA 1993;270:350-353.
189. Doebbeling BN, Pfaller MA, Houston AK, et al. Removal of nosocomial pathogens from the contaminated glove: implications for glove reuse and handwashing. Ann Intern Med 1988;109:394-398.
190. Werheim HF, Vos MC, Ott A, et al. Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: a randomized study. Ann Intern Med 2004;140:419-425.
191. Miller MA, Dascal A, Portnory J, et al. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996;17:811-813.
192. Torvaldsen S, Roberts C, Riley TV. The continuting evolution of methicillin-resistant Staphylococcus aureus in western Australia. Infect Control Hosp Epidemiol 1999;20:133-135.
193. Vasquez JE, Walker ES, Franzus BW, et al. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans' Affairs hospital. Infect Control Hosp Epidemiol 2000;21:459-464.
194. Fraunfelder FT, Bagby GC, Kelly DJ. Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol. Am J Ophthalmol 1982;93:356-360.
195. Doona M, Walsh JB. Use of chloramphenicol as topical eye medication: Time to cry halt? BMJ 1995;310:1217-1218.
196. Marcinak JF, Frank AL. Treatment of community-acquired methicillin-resistant Staphylococcus aureus in children. Curr Opin Infect Dis 2003;16:265-269.
197. Panagea S, Perry JD, Gould FK. Should clindamycin be used as treatment of patients with infections caused by erythromycin-resistant staphylococci? J Antimicrob Chemother 1999;44:581-582.
198. Rao GG. Should clindamycin be used in treatment of patients with infections caused by erythromycin-resistant staphylococci? J Antimicrob Chemother 2000;45:715.
199. Drinkovic D, Fuller ER, Shore KP, et al. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrob Chemother 2001;48:315-316.
200. Siberry GK, Tekle T, Carroll K, et al. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003;37:1257-1260.
201. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-1081.
202. Kowalski RP, Karenchak LM, Romanowski EG. Infectious disease: changing antibiotic susceptibility. Ophthalmol Clin North Am 2003;16:1-9.
203. Ling ML, Tan PL. In vitro activity of moxifloxacin against local bacterial isolates. Ann Acad Med Singapore 2001;30:607-610.
204. Abb J. In vitro activity of linezoid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin, and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method. Diag Microbiol Infect Dis 2002;43:319-321.
205. Tsuji H, Tsuru T, Okuzumi K. Detection of methicillin-resistant Staphylococcus aureus in donor eye preservation media by polymerase chain reaction. Jpn J Ophthalmol 1998;42:352-356.
206. Michel M, Gutmann L. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Lancet 1997;349:1901-1906.
207. Pillai SK, Sakoulas G, Wennersten C, et al. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J Infect Dis 2002;186:1603-1607.
208. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670-1673.
209. Linden PK. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med 1998;104(5A):24S-33S.
210. Schindler CA, Schuhart VT. Lysostaphin: a new bacteriolytic agent for the Staphylococcus. Proc Natl Acad Sci USA 1965;51:414-421.
211. Sloan GL, Robinson JM, Kloos WE. Identification of 'Staphylococcus staphylolyticus' NRRL B-2628 as biovar of Staphylococcus simulans. Int J Bacteriol 1982;32:170-174.
212. Dajcs JJ, Hume EB, Moreau JM, et al. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Invest Ophthalmol Vis Sci 2000;41:1432-1437.
213. Dajcs JJ, Thibodeaux BA, Hume EB, et al. Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit. Curr Eye Res 2001;22:451-457.
214. Kessler E, Safrin M, Olson JC, et al. Secreted LasA protease of Pseudomonas aeruginosa is a staphylolytic protease. J Biol Chem 1993;268:7503-7508.
215. Kessler E. β-lytic endopeptidases. Methods Enzymol 1995;248:740-756.
216. Kessler E, Ohman DE. Staphylolysin. In: Barrett AJ, Rawlings ND, Woessner JF, eds. Handbook of Proteolytic Enzymes. London: Academic Press; 1998:1476-1478.
217. Barequet IS, Ben Simon GY, Safrin M, et al. Pseudomonas aeruginosa LasA protease in treatment of experimental staphylococcal keratitis. Antimicrob Agents Chemother 2004;48:1681-1687.
218. Callegan MC, Hill JM, Insler MS, et al. Methicillin-resistant Staphylococcus aureus keratitis in the rabbit: therapy with ciprofloxacin, vancomycin, and cefazolin. Curr Eye Res 1992;11:1111-1119.
219. Fattom AI, Sarwar J, Ortiz A, et al. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 1996;64:1659-1665.
220. Lee JC, Park JS, Shepherd SE, et al. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 1997;65:4146-4151.
221. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002;346:491-496.